Business Context and Reporting Period
This Form 6-K filing by I-Mab (not Novabridge Biosciences) covers the month of August 2025. The registrant is a foreign private issuer headquartered in Rockville, MD, with principal executive offices at 2440 Research Boulevard, Suite 400. The filing announces an underwritten public offering of American Depositary Shares (ADSs).
Key Financial Metrics
- Offering Size: 33,333,330 ADSs (representing 76,666,659 ordinary shares).
- Offering Price: $1.95 per ADS.
- Gross Proceeds: Approximately $65 million (before underwriting discounts and expenses).
- Underwriter: Leerink Partners LLC as representative.
- Expected Closing Date: On or about August 5, 2025.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transaction announcement rather than a periodic financial report.
Material Changes
The primary material change is the execution of an Underwriting Agreement on August 1, 2025, to raise capital. This represents a significant increase in the company's share count and expected cash inflow upon closing. The offering is made pursuant to a shelf registration statement (File No. 333-286954) declared effective on May 15, 2025.
Guidance, Outlook, and Risks
Outlook: Management expects the offering to close on or about August 5, 2025, subject to customary closing conditions. The company issued a press release on August 1, 2025, to announce the transaction.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to market risks, uncertainties, and the satisfaction of closing conditions. The company undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the exact number of ordinary shares issued and the final share count post-offering.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Check for any subsequent filings regarding the use of proceeds or changes in the offering terms.